Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) dropped 9.4% on Wednesday . The company traded as low as $0.14 and last traded at $0.14. Approximately 549,894 shares changed hands during mid-day trading, an increase of 15% from the average daily volume of 479,329 shares. The stock had previously closed at $0.16.
Hemispherx BioPharma (NYSEAMERICAN:HEB) last released its quarterly earnings results on Monday, April 1st. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.04. The firm had revenue of $0.24 million for the quarter.
Hemispherx BioPharma Company Profile (NYSEAMERICAN:HEB)
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Article: Municipal Bonds
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.